Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome (URIC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by National Taiwan University Hospital
Sponsor:
Information provided by (Responsible Party):
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01818505
First received: March 21, 2013
Last updated: April 11, 2014
Last verified: April 2014

March 21, 2013
April 11, 2014
March 2013
December 2015   (final data collection date for primary outcome measure)
development of metabolic syndrome or cardiovascular events [ Time Frame: 36 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01818505 on ClinicalTrials.gov Archive Site
Acute myocardial infarct or stroke [ Time Frame: 36 months or more ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome
The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome

Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. Many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. In the present study, the investigators will analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. The investigators expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities.

Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. Many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. In the present study, we'll analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/ asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. We expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities.

Patient eligibility:

  1. Patients with gout
  2. Patients with asymptomatic hyperuricemia
  3. Patients of osteoarthritis but without hyperuricemia and gout Exclusion Criteria: Patients younger than 20 years old
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

serum

Non-Probability Sample

General population

  • Antiphospholipid Syndrome
  • Endothelial Dysfunction
  • Hyperuricemia
  • Gout
  • Metabolic Syndrome
Not Provided
  • Gouty arthritis
    Patient with gouty arthritis
  • Asymptomatic hyperuricemia
    Patient with asymptomatic hyperuricemia
  • OA without hyperuricemia
    Patient of osteoarthritis but without hyperuricemia and gout
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
210
Not Provided
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patient with gouty arthritis
  2. Patient with asymptomatic hyperurecemia
  3. Patient of osteoarthritis but without hyperuricemia and gout

Exclusion Criteria:

1.Patient younger than 20 y/o.

Both
20 Years and older
No
Contact: Yu-Min Kuo, M.D. 886972655701 543goole@gmail.com
Taiwan
 
NCT01818505
URIC
Yes
National Taiwan University Hospital
National Taiwan University Hospital
Not Provided
Principal Investigator: Yu-Min Kuo, MD National Taiwan University Hospital
National Taiwan University Hospital
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP